DUBLIN, Dec. 7, 2022 /PRNewswire/ -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to ResearchAndMarkets.com's offering.
The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? The publisher looks at Price and Volume Outlooks by type of cancer. This report provides detailed analysis. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test. Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring. Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. 2 Introduction and Market Definition
3.1 Players in a Dynamic Market
3.1.2 Diagnostic Test Developer
3.1.7 Public National/regional Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.11 Certification Body
3.2.2 Precancerous conditions
3.2.3 Inflammatory conditions
3.4 The Situation Today - Biopsy Analysis
3.5 Evidence of Cancer - Liquid Biopsy Technology 3.5.1 The Big Picture on Liquid Biopsy Technology
3.5.3 Application of CTCs
3.5.4 CellSearch Detection- Ultimate Sensitivity
3.5.5 Epic Sciences Detection- Imaging Takes the Lead 3.5.6 Maintrac Detection - The Microscope
3.5.10 Exosomes and Micro Vesicles - New Kid on the Block
3.6 Cancer Treatment Protocol Under Siege 3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
3.6.2 The Cancer Screening Market Opportunity 3.6.2.1 GRAIL - What Is It? 3.6.3.1 The Role of Risk Assessment
3.6.3.3 Monitoring Disease - What Is It?
3.6.4 Phases of Adoption - Looking into The Future
3.6.5 The Promise of Liquid Biopsy
3.7 Structure of Industry Plays a Part
3.7.3 Physician Office Lab's
3.7.4 Physician's and POCT
4.1 Factors Driving Growth
4.1.1 Non-Invasive Game Changer
4.2 Factors Limiting Growth
4.2.3 Protocol Resistance
4.2.4 Initial Adoption Cost
4.3 Instrumentation and Automation
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Impact of NGS on pricing
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay
5 Liquid Biopsy Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 PamGene Expanding Liquid Biopsy Assays
5.3 Liquid Biopsy Firm Hedera Dx Raises €14M 5.5 Precision Oncology Dx Access Varies Widely in Europe
5.6 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic 5.7 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
5.9 Dxcover Advances Multicancer Detection Platform
5.11 Illumina Sues Guardant Health Over Patents 5.13 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies 5.14 IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.18 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.19 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding 5.20 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition 5.23 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition 5.26 Liquid Biopsy NGS Panels - Diverse Test Claims 5.28 Natera Liquid Biopsy Test Coverage to Expand
5.29 Freenome Closes Financing to Support Early Cancer Detection Trial 5.30 C$2.6M Liquid Biopsy Initiative
5.33 Inivata launches RaDaRT for the detection of residual disease and recurrence 5.34 Liquid Biopsy Assay Detects 50+ Types of Cancer 5.35 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy 6 Profiles of Key Players
6.12 Baylor Miraca Genetics Laboratories
6.14 Becton, Dickinson and Company
6.37 Cytolumina Technologies Corp
6.68 Menarini Silicon Biosystems
6.73 Myriad Genetics/Myriad RBM 7 The Global Market for Liquid Biopsy Diagnostics
7.1 Global Market Overview by Country
7.2 Global Market by Cancer - Overview 7.3 Global Market by Usage - Overview
7.4 Global Market by Place - Overview
7.4.1 Table - Global Market by Place
7.5 Global Market by Marker - Overview
7.6 Global Market by Product - Overview
8 Global Liquid Biopsy Diagnostic Markets - By Cancer 9 Global Liquid Biopsy Diagnostic Markets - by Usage
9.2 Chart - Screening Growth
10 Global Liquid Biopsy Diagnostic Markets - by Place
11 Global Liquid Biopsy Diagnostic Markets - by Marker
11.1 Circulating Tumor Cell 12 Global Liquid Biopsy Diagnostic Markets - by Product
For more information about this report visit https://www.researchandmarkets.com/r/r28spe
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg